Navigation Links
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Date:9/24/2010

PHILADELPHIA, BOONTON, N.J. and BRUSSELS, Sept. 24 /PRNewswire/ -- Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. (OTC Bulletin Board: UGNE) today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.  The data are being presented at the 2010 Osteoarthritis Research Society International (OARSI) World Congress in Brussels, Belgium.  Unigene produces Fortical® nasal calcitonin product for the treatment of postmenopausal osteoporosis and Tarsa's oral calcitonin, which is licensed from Unigene, is in a Phase III trial for the treatment of osteoporosis.

The study was designed to identify whether the combination of salmon calcitonin and other recognized and experimental anti-arthritis drugs can produce additive or synergistic effects in reducing collagen degradation in a bovine in vitro collagen matrix model.  The results were reported by Dr. James P. Gilligan, Chief Scientific Officer of Tarsa, and Dr. Nozer Mehta, Vice President, Biological Research and Development at Unigene.

Dr. Gilligan commented, "The impetus for this study is the fact that osteoarthritis is a complex, multi-modal disease, so combination therapy may be the most effective approach to treatment.  We hypothesized that a potentially disease-modifying osteoarthritis drug such as calcitonin given in combination with other anti-arthritic agents might result in additive or synergistic effects."

In the data presented, calcitonin did exhibit synergistic effects in reducing collagen degradation when combined with low doses of each of two other experimental anti-arthritis agents, while none of the agents reduced collagen release on its own at the concentrations used.

Dr. Mehta noted, "While preliminary, these data lend support to the c
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NJ (PRWEB) November 25, 2014 ... has officially joined the Morris County (New Jersey) ... which is a leading business organization in the ... opportunity to further engage some key clients in ... operations in the geographic area. Membership enables Whitehouse ...
(Date:11/26/2014)... 2014 Global biostimulants market is ... at an estimated CAGR of 12.5%. In order ... products with least ecological impacts, farmers are looking ... boost crop yield more effectively & efficiently. Biostimulants ... improve the return on investments. , Leading companies ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/24/2014)... UAE, November 24, 2014 Five ... Bin Rashid Al Maktoum Awards for Medical Sciences", in ... Dubai, United Arab Emirates , on 15 December ... , The Carter Center which won the ... actively involved in numerous programs that aim to improve ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... ended March 31, 2009. Arena reported a net loss allocable ... $50.6 million, or $0.68 per share, compared to a net ... 2008 of $55.0 million, or $0.75 per share. "Receiving the ...
... Inc. (Nasdaq: IDIX ) announced today that Idenix ... Bank 2009 Health Care Conference on Monday, May 18, 2009 ... and archived webcast of the company presentation can be accessed ... www.idenix.com . Please log in approximately ...
... 18, 2009 SAN DIEGO, May 11 Neurocrine Biosciences, ... Kevin Gorman, President and Chief Executive Officer of Neurocrine ... Annual Health Care Conference in Boston. The live presentation ... Eastern Time (ET)/2:05 p.m. Pacific Time (PT). The ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Hospital (MGH) Cancer Center have identified a subgroup of ... drug cisplatin, rarely used in the treatment of breast ... of this sensitivity, which may help identify patients most ... will be tested in a clinical trial anticipated to ...
... delivered into the tumors of stage 4 lung cancer ... phase I clinical trial at The University of Texas ... found to be active in the metastatic non-small cell ... first-in-human study and we've seen an exciting proof of ...
... cut back on the amount of salt in their diet could ... to a report on bmj.com today. , Researchers in ... risk of death from cardiovascular disease by up to a fifth. ... diseases linked to the heart or arteries, for example a stroke ...
Cached Biology News:Molecular signature may identify cisplatin-sensitive breast tumors 2Molecular signature may identify cisplatin-sensitive breast tumors 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2Eating less salt could prevent cardiovascular disease 2
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
Biology Products: